In short
Clinical trials are studying 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE as part of research for hallucinations and delusions linked to Alzheimer’s disease psychosis. The main goal is to compare this treatment with placebo and measure whether symptoms improve in adults with this condition.
Key points
- Clinical trials are investigating 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE for hallucinations and delusions linked to Alzheimer’s disease psychosis. The study listed here is a Phase 2 interventional trial, which means researchers are testing whether the treatment may help and are also watching its safety. It compares the study treatment with placebo in adults with this condition. The main result being measured is the change in the NPI-C H+D score from the start of the study to Week 7. The planned enrollment is 300 participants.
Trial overview
The available trial is studying 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE in people with hallucinations and delusions associated with Alzheimer’s disease psychosis.1
The study title says it is evaluating ML-007C-MA for this condition, and the listed intervention includes placebo for ML-007C-MA bilayer tablet and 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE given by mouth.1
This is an interventional study, which means researchers give a treatment and compare outcomes between groups.1
Study design and phase
The trial is in Phase 2.1
Phase 2 studies are used to look more closely at whether a treatment may help and to continue checking safety and response in the target group.1
The study status is Authorised, and the planned enrollment is 300 participants.1
Who can participate
The target population is adults with hallucinations and delusions associated with Alzheimer’s disease psychosis.1
The source data do not list more detailed entry rules, such as age limits, test results, or other health requirements.1
What is being measured
The main endpoint is the NPI-C H+D score, which is a rating used to measure hallucinations and delusions.1
Researchers will measure the change from baseline to Week 7, so they are looking at how symptoms change from the start of the study to the seventh week.1
The brief summary says the goal is to evaluate the efficacy of ML-007C-MA compared with placebo for hallucinations and delusions associated with ADP as measured by the NPI-C H+D score.1
Trial summary
In simple terms, this study asks whether 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE, as part of ML-007C-MA, can improve hallucinations and delusions in Alzheimer’s disease psychosis better than placebo.1
The trial is focused on symptom change over 7 weeks, and it plans to include 300 people.1
Because only one trial is provided, the current evidence summary is limited to this Phase 2 study in people with Alzheimer’s disease psychosis.1